- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Novartis makes progress in the fight to eliminate leprosy worldwide
17 January 2013 • Author: Novartis
Novartis celebrates the one-year anniversary of an unprecedented, coordinated effort to eliminate or control 10 neglected tropical diseases (NTDs) by 2020. The commitment was captured in the landmark London Declaration on NTDs in which Novartis and a group of partners, including the World Health Organization (WHO), government officials from the United States, United Kingdom and United Arab Emirates governments, the World Bank and non-governmental organizations, and 13 other pharmaceutical companies pledged new and extended commitments to fight NTDs. Its goal is to improve the lives of the estimated over one billion people affected by these diseases worldwide.
In the year since its launch, Novartis and its partners have worked toward fulfilling their commitments and announced their progress in the First Annual Report on the London Declaration on NTDs released today.
“The challenges in delivering healthcare in developing countries are considerable: poor infrastructure, poverty, lack of trained health workers, and many more,” said Joseph Jimenez, CEO of Novartis. “No one company can solve these issues alone. We’re proud to be working with so many dedicated partners to address the most pressing health problems in the developing world today.”
Novartis and the Novartis Foundation for Sustainable Development (NFSD) have a long-term commitment to leprosy treatment and control, having provided over USD 110 million for patients worldwide to date. Since 2000, through the WHO, Novartis has donated multidrug therapy (MDT) valued at over USD 80 million, helping to treat over 5 million patients. Last year, Novartis continued its work with the WHO by extending its drug donation program through the year 2020.
NFSD has been active in the fight against leprosy for more than 25 years, providing more than CHF 30 million to help reduce the stigma attached to leprosy, prevent disabilities and help patients reintegrate in society. To facilitate the drug donation, NFSD is currently developing innovative approaches to enhance leprosy services. In Tanzania, the foundation added the tracking of leprosy and tuberculosis (TB) medicines to the SMS for Life public-private partnership led by Novartis and piloted across Tanzania, with over 500 facilities now trained and reporting on a weekly basis.
SMS for Life is a first-of-its-kind public-private partnership led by Novartis. Developed under the umbrella of the Roll Back Malaria Partnership and supported by the Tanzanian Ministry of Health and Social Welfare, IBM, Medicines for Malaria Venture (MMV), the Swiss Agency for Development and Cooperation (SDC), Vodacom and Vodafone, the program was started to track malaria drug supplies in public health facilities in sub-Saharan Africa. Through the use of mobile phones and electronic mapping technology, SMS for Life provides transparent information that can be used to eliminate drug stock-outs and increase access to essential medicines.
In Cambodia, NFSD pilots a methodology of active case finding by tracking former leprosy patients. The foundation is also developing a tele-health solution in the Amazon in Brazil to improve the quality of leprosy services. In the Philippines, the foundation supports the establishment of a task-force to identify and advance new approaches that help maintain adequate leprosy services even in times of low endemicity. In collaboration with Novartis Philippines and the Department of Health, the foundation launched a contest in January 2013 inviting participants to share best practices and innovative ideas in fighting leprosy. Finally, the Novartis Comprehensive Leprosy Care Association (NCLCA) in India, supported by NFSD, helps former patients with deformities reintegrate into society through fostering disability care, including surgeries, grip aids and physiotherapy.
About Novartis access-to-healthcare initiatives
Novartis has a long-term commitment to enhancing access to healthcare in the developing world. Novartis works to discover vaccines and medicines for neglected diseases through two wholly-owned research institutes: The Novartis Institute for Tropical Diseases (NITD) in Singapore and The Novartis Vaccines Institute for Global Health (NVGH) in Italy. Novartis also runs the Novartis Malaria Initiative, which is one of the healthcare industry’s largest access-to-medicine programs worldwide. Since 2001, Novartis has worked with a range of organizations to ensure effective delivery of our antimalarial medicine Coartem, providing more than 500 million treatments without profit.
In 2011, Novartis access-to-medicine programs reached more than 89 million patients and together with our research institutes for diseases of the developing world, are valued at USD 1.7 billion, or 3% of net sales.
About multidrug therapy (MDT) in treating leprosy
Since 1985, more than 14 million people living with leprosy worldwide have been treated by MDT, the treatment recommended by the WHO, shrinking the worldwide prevalence by approximately 95%. According to the WHO in 2011 there were 219,075 new cases reported, from a total of 105 countries. Despite these successes, leprosy control remains at a critical juncture and knowledge of the disease is becoming less common. Moving forward, early detection and continued availability of free treatment are essential.
The development of MDT changed the face of leprosy dramatically. MDT consists of three drugs (rifampicin, clofazimine and dapsone), two of which (rifampicin and clofazimine) were developed in the research laboratories of Novartis in the 1980s. Multidrug therapy has made it possible to treat patients, interrupt the transmission of leprosy and prevent disabilities. Even patients with the severest form of the disease show visible clinical improvement within weeks of starting treatment.
ABB Analytical Measurement ABL&E Group ABS Laboratories ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Andor Technology Astell Scientific Ltd Axis-Shield Diagnostics Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAMO Software AS Celsis International Charles Ischi AG | Kraemer Elektronik ChemAxon Cherwell Laboratories CI Precision Cobalt Light Systems Comark Instruments Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Dotmatics Limited Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl HunterLab IDBS IONICON Analytik GmbH kbiosystems ltd L.B. Bohle Maschinen + Verfahren GmbH LabWare Linkam Scientific Instruments Limited MKS Umetrics Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc Portalis Ltd Powder Systems Limited (PSL) RADWAG Reach Separations ReAgent Russell Finex Limited Source BioScience Spectrum®Labs.com Stratech Scientific Limited Takara Clontech Thermal Detection Ltd. Tuttnauer Vaisala Ltd VIAVI OSP Waters Corporation Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Ytron-Quadro (UK) Limited Yusen Logistics